



GP-1642

#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 107823.146CON)

In re Application of: Madiyalakan et al.) Examiner: To Be Assigned
Serial No. 09/871,339) Group Art Unit: 1642
Filing Date: May 31, 2001)

For: METHOD AND COMPOSITION FOR RECONFORMING MULTI-EPITOPIC ANTIGENS
TO INITIATE AN IMMUNE RESPONSE

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 8/6/01

Diana Havens
Diana Havens

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for filing in the above-identified patent application are the following documents:


1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (cited references were submitted previously in parent application no. 08/913,290);
3. Certificate of First Class Mailing; and
4. Return Postcard.

RECEIVED
AUG 10 2001
TC 1700 MAIL ROOM

U.S.S.N. 09/871,339
Page Two

No fees are believed to be due in connection with this submission. However, please charge any fees which might be due or credit any overpayment to our Deposit Account No. 08-0219.

Respectfully submitted,



Nancy Chiu, Ph.D.
Reg. No. 43,545
Agent for Applicants

Date: August 6, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 107823.146CON)

In re Application of: Madiyalakan et al.) Examiner: To Be Assigned
Serial No. 09/871,339) Group Art Unit: 1642
Filing Date: May 31, 2001)

For: METHOD AND COMPOSITION FOR RECONFORMING MULTI-EPITOPIC ANTIGENS
TO INITIATE AN IMMUNE RESPONSE

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 8/6/01


Diana Havens

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the attached form PTO-1449, which cites references for filing in the above-referenced application, copies of which were already filed in the parent application (U.S. Patent Application No. 08/913,290, now U.S. Patent No. 6,241,985). This information disclosure statement is being filed under 37 C.F.R. § 1.97 (b) before the mailing date of the first Office Action, therefore no fee is believed to be due.


This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents do not constitute prior art under United States law, Applicants reserve the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

U.S. Patent Application No. 09/871,339
Page Two

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.

Please also charge any fees which might be due in connection with this matter to Deposit Account No. 08-0219. If there are any questions, please call the undersigned at the telephone number indicated below.


Respectfully submitted,



Nancy Chiu, Ph.D.
Reg. No. 43,545
Agent for Applicants

Date: August 6, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



Sub. For, PTO-1449				Docket Number 107823.146CON		Application Number 09/871,339	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Madiyalakan et al.			
				Filing Date May 31, 2001		Group Art Unit 1642	
Sheet	1	OF	2				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,940,670	7/10/90	Rhodes			
	4,950,480	8/21/90	Barber et al.			
	4,997,762	3/05/91	Hanna, Jr. et al.			
	5,053,224	10/01/91	Koprowski et al.			
	5,183,657	2/02/93	Buurman			
	5,308,614	5/03/94	Hakomori			
	5,194,254	3/16/93	Barber et al			
	5,389,530	2/14/95	Hakomori			
	5,478,556	12/26/95	Elliott et al.			
	5,500,215	3/19/96	Hakomori			
	5,009,888	4/23/91	Dunn			
	5,518,723	5/21/96	Devico et al.			
	5,013,547	5/07/91	Sweet et al.			

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 89/01629	02/23/89	PCT				
	PCT/US90/03142	STAT	PCT				
	PCT/US92/11334	7/08/93	PCT				
	PCT/EP94/01719	8/12/94	PCT				
	EP 0288082	04/22/88	Europe				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
A1	Madiyalakan R et al., Hybridoma, 14:199-203 (1995)	
A2	Ghiron CA et al., Photochemistry and Photobiology, 7: 87-92 (1968)	
A3	Prodouz KN et al., Blood 70:589-592 (1987)	
A4	Jose SA et al., Molecular Immunology 24: 1145-1150 (1987)	
A5	Kleckowski A et al., Photochem. Photobiol. 1: 299-304 (1962)	
A6	Murray R et al., J.A.M.A. 8-14 (1955)	
A7	Kallenbach NR et al., Curr Stud Hematol Blood Transfus. 70-82 (1989)	
A8	Sykes TR et al., The Journal of Nuclear Medicine 36:1913-1922 (1995)	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Sheet

2

OF

2

Docket Number

107823.146CON

Application Number

09/871,339

Applicant

Madiyalakan et al.

Filing Date

May 31, 2001

Group Art Unit

1642

B1	Baum RP et al., Hybridoma 12: 583-589 (1993)
B2	Baum RP et al., Cancer 73:1121-1125 (1994)
B3	Noujaim AA et al., Current Tumor Diagnosis 823-829 (1994)
B4	Chatterjee MB et al., Cancer Immunol Immunother 38: 75-82 (1994)
B5	Thomson AW et al., Clin Exp Immunol 98: 351-357 (1994)
B6	Kehoe S, International Journal of Oncology 6:451-458 (1995)
B7	Lanzavecchia A, Science 260: 937-944 (1993)
B8	Wagner UA et al., Biotechnology Therapeutics 3: 81-89 (1992)
B9	Nemazee et al., PNAS 79: 3828-3832 (1982)
B10	Stevenson FK et al., Immunol 2:16-19 (1994)
B11	Leoni et al., Int J Cancer 40: 592-597 (1987)
B12	Jose et al., Mol Immunol 24:1145-1150 (1987)
B13	Imai et al., Acta Pathol, Japan 29: 43-49 (1989)
B14	Gura, Science 278: 1041-1042 (1997)
B15	Herbert et al., Dictionary of Immunology, Academic Press, London, pp 58, 59, 72, 73, and 154 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.